• Explore /
  • Poster
  • / Genetic variations in the β2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.

Genetic variations in the β2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.

Abstract Poster

Authors

null

Madiha Naseem

Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA

Madiha Naseem , Sebastian Stintzing , Shu Cao , Alberto Puccini , Ryuma Tokunaga , Francesca Battaglin , Afsaneh Barzi , Martin D. Berger , Shivani Soni , Michelle McSkane , Wu Zhang , Joshua Millstein , Volker Heinemann , Heinz-Josef Lenz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Tumor Biology

Track

Tumor Biology

Sub Track

Tumor-Based Biomarkers

Citation

J Clin Oncol 36, 2018 (suppl; abstr 12107)

DOI

10.1200/JCO.2018.36.15_suppl.12107

Abstract #

12107

Poster Bd #

220

Abstract Disclosures

Similar Posters

First Author: Madiha Naseem

First Author: Francesca Battaglin

First Author: Madiha Naseem

First Author: Ilse Van Oostrum